Abstract
Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders and it is characterized by episodes of abdominal pain and altered bowel functions. The specific bowel disturbances of diarrhea, constipation or an alternation between the two defines the IBS subtypes of diarrhea-predominant, constipation-predominant, and mixed or alternating IBS. Because of the abnormalities in bowel states associated with each IBS subtype, it is not likely that one agent would successfully treat all three subtypes. As a result, clinical trials have focused, for the most part, on one IBS subtype. Over the past 2 decades very few agents have achieved regulatory approval for the treatment of IBS. In the present article we review publications reporting on phase 2 and phase 3 studies evaluating agents to potentially be used in the treatment of patients with IBS.
Keywords: Irritable bowel syndrome, diarrhea-predominant, constipation-predominant, abdominal pain, bowel functions, gastrointestinal disorders, diarrhea, chronic, placebo, Alosetron
Reviews on Recent Clinical Trials
Title:Clinical Trials in Irritable Bowel Syndrome: A Review
Volume: 8 Issue: 1
Author(s): Claire M. Ervin and Allen W. Mangel
Affiliation:
Keywords: Irritable bowel syndrome, diarrhea-predominant, constipation-predominant, abdominal pain, bowel functions, gastrointestinal disorders, diarrhea, chronic, placebo, Alosetron
Abstract: Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders and it is characterized by episodes of abdominal pain and altered bowel functions. The specific bowel disturbances of diarrhea, constipation or an alternation between the two defines the IBS subtypes of diarrhea-predominant, constipation-predominant, and mixed or alternating IBS. Because of the abnormalities in bowel states associated with each IBS subtype, it is not likely that one agent would successfully treat all three subtypes. As a result, clinical trials have focused, for the most part, on one IBS subtype. Over the past 2 decades very few agents have achieved regulatory approval for the treatment of IBS. In the present article we review publications reporting on phase 2 and phase 3 studies evaluating agents to potentially be used in the treatment of patients with IBS.
Export Options
About this article
Cite this article as:
M. Ervin Claire and W. Mangel Allen, Clinical Trials in Irritable Bowel Syndrome: A Review, Reviews on Recent Clinical Trials 2013; 8 (1) . https://dx.doi.org/10.2174/1574887111308010003
DOI https://dx.doi.org/10.2174/1574887111308010003 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
ABC Transporters in Extrahepatic Tissues: Pharmacological Regulation in Heart and Intestine
Current Medicinal Chemistry Small Molecule Antagonists of Integrin Receptors
Current Medicinal Chemistry Targeting Soluble Epoxide Hydrolase for Inflammation and Pain - An Overview of Pharmacology and the Inhibitors
Inflammation & Allergy - Drug Targets (Discontinued) Potential Benefits and Limits of Psychopharmacological Therapies in Pervasive Developmental Disorders
Current Clinical Pharmacology Antisense Therapy for Cardiovascular Diseases
Current Pharmaceutical Design Tumor Necrosis Factor Blocking Therapy and Congestive Heart Failure in Patients with Inflammatory Rheumatic Disorders: A Systematic Review
Current Medicinal Chemistry Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets Suppression of Inflammatory and Allergic Responses by Pharmacologically Potent Fungus Ganoderma lucidum
Recent Patents on Inflammation & Allergy Drug Discovery Synthesized Drug from Medicinal Plant phytochemicals Effectively Targets ECM1 Gene Mutations in Ulcerative Colitis
Letters in Drug Design & Discovery MTHFR Gene Polymorphism and Diabetic Retinopathy
Current Diabetes Reviews Molecular Mechanisms Underlying Psychological Stress and Cancer
Current Pharmaceutical Design Pharmacological Targeting of the Hsp70 Chaperone
Current Topics in Medicinal Chemistry The Brain-Immune-Gut Triangle: Innate Immunity in Psychiatric and Neurological Disorders
Current Immunology Reviews (Discontinued) Aging and DNA Methylation
Current Chemical Biology Mechanisms of Neutrophil-mediated Disease: Innovative Therapeutic Interventions
Current Pharmaceutical Design Antioxidant Therapy for Prevention of Inflammation, Ischemic Reperfusion Injuries and Allograft Rejection
Cardiovascular & Hematological Agents in Medicinal Chemistry Melatonin and Respiratory Diseases: A Review
Current Topics in Medicinal Chemistry Clinical Uses of Melatonin: Evaluation of Human Trials
Current Medicinal Chemistry Therapeutic Effect of Ghrelin in the Course of Ischemia/Reperfusion-Induced Acute Pancreatitis
Current Pharmaceutical Design Cardioprotective Effects of Indian Gooseberry (Emblica officinalis Gaertn) and its Phytochemicals: A Review
Current Nutrition & Food Science